narcotic antagonists

Summary

Summary: Agents inhibiting the effect of narcotics on the central nervous system.

Top Publications

  1. ncbi Opioid peptides and the control of human ingestive behaviour
    Martin R Yeomans
    Laboratory of Experimental Psychology, University of Sussex, Brighton, Sussex BN1 9QG, UK
    Neurosci Biobehav Rev 26:713-28. 2002
  2. pmc Dynorphin, stress, and depression
    Allison T Knoll
    Behavioral Genetics Laboratory, Department of Psychiatry, Harvard Medical School, McLean Hospital, MRC 217, 115 Mill Street, Belmont, MA 02478, USA
    Brain Res 1314:56-73. 2010
  3. ncbi Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo
    Frank L Greenway
    Pennington Biomedical Research Center, Louisiana State University System, 6400 Perkins Road, Baton Rouge, Louisiana 70808, USA
    J Clin Endocrinol Metab 94:4898-906. 2009
  4. ncbi Naltrexone for the treatment of obesity: review and update
    Michael William Lee
    Scripps Clinic Center for Weight Management, 12395 El Camino Real, Suite 317, San Diego, CA 92130, USA
    Expert Opin Pharmacother 10:1841-5. 2009
  5. pmc Nalfurafine prevents 5'-guanidinonaltrindole- and compound 48/80-induced spinal c-fos expression and attenuates 5'-guanidinonaltrindole-elicited scratching behavior in mice
    S Inan
    Department of Pharmacology, Temple University School of Medicine, 3420 North Broad Street, Philadelphia, PA 19140, USA
    Neuroscience 163:23-33. 2009
  6. ncbi Association of µ-opioid receptor (OPRM1) gene polymorphism with response to naltrexone in alcohol dependence: a systematic review and meta-analysis
    Antonio Javier Chamorro
    Department of Internal Medicine, Hospital of Ourense, Spain
    Addict Biol 17:505-12. 2012
  7. pmc Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful?
    NATALYA C MAISEL
    Center for Health Care Evaluation, VA Palo Alto Health Care System 152MPD, Menlo Park, CA 94025, USA
    Addiction 108:275-93. 2013
  8. ncbi Activation of stress-related hypothalamic neuropeptide gene expression during morphine withdrawal
    Cristina Nunez
    Department of Pharmacology, University of Murcia, Murcia, Spain
    J Neurochem 101:1060-71. 2007
  9. ncbi Pharmacological properties of JDTic: a novel kappa-opioid receptor antagonist
    Ivy Carroll
    Organic and Medicinal Chemistry, Research Triangle Institute, Research Triangle Park, North Carolina, USA
    Eur J Pharmacol 501:111-9. 2004
  10. ncbi Chronic exposure to mu-opioid agonists produces constitutive activation of mu-opioid receptors in direct proportion to the efficacy of the agonist used for pretreatment
    J G Liu
    Department of Pharmacology and Toxicology, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA
    Mol Pharmacol 60:53-62. 2001

Research Grants

  1. BIOLOGICAL DISPOSITION OF NARCOTIC ANALGESICS IN MAN
    CARL HUG; Fiscal Year: 1980
  2. BEHAVIORAL PHARMACOLOGY OF NARCOTIC ANTAGONISTS
    STEPHEN HOLTZMAN; Fiscal Year: 2002
  3. PHARMACOLOGY OF NARCOTICS & NARCOTIC ANTAGONISTS
    JAMES MC KEARNEY; Fiscal Year: 1991
  4. EFFECTIVE NARCOTIC ANTAGONISTS
    Jack Fishman; Fiscal Year: 1980
  5. CHARACTERIZATION OF ETHANOL WITHDRAWAL
    Harbans Lal; Fiscal Year: 1992
  6. Gene Gun Technology, Opioids, and Corneal Diseases
    IAN ZAGON; Fiscal Year: 2003
  7. Cognitive-Behavioral Therapy for Pathological Gambling
    Jon Grant; Fiscal Year: 2008
  8. PAIN REGULATORY SYSTEM DYSFUNCTION IN CHRONIC PAIN
    Stephen Bruehl; Fiscal Year: 2002
  9. Anger Expression, Opioid Dysfunction, and Chronic Pain
    Stephen Bruehl; Fiscal Year: 2009
  10. Pain Regulatory Dysfunction in Chronic Pain
    Stephen Bruehl; Fiscal Year: 2007

Detail Information

Publications355 found, 100 shown here

  1. ncbi Opioid peptides and the control of human ingestive behaviour
    Martin R Yeomans
    Laboratory of Experimental Psychology, University of Sussex, Brighton, Sussex BN1 9QG, UK
    Neurosci Biobehav Rev 26:713-28. 2002
    ..The review also highlights the need for further empirical work in order to elucidate further the role of opioid peptides in human ingestive behaviour...
  2. pmc Dynorphin, stress, and depression
    Allison T Knoll
    Behavioral Genetics Laboratory, Department of Psychiatry, Harvard Medical School, McLean Hospital, MRC 217, 115 Mill Street, Belmont, MA 02478, USA
    Brain Res 1314:56-73. 2010
    ....
  3. ncbi Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo
    Frank L Greenway
    Pennington Biomedical Research Center, Louisiana State University System, 6400 Perkins Road, Baton Rouge, Louisiana 70808, USA
    J Clin Endocrinol Metab 94:4898-906. 2009
    ..The efficacy of current centrally acting obesity pharmacotherapies is limited by compensatory mechanisms that mitigate weight loss...
  4. ncbi Naltrexone for the treatment of obesity: review and update
    Michael William Lee
    Scripps Clinic Center for Weight Management, 12395 El Camino Real, Suite 317, San Diego, CA 92130, USA
    Expert Opin Pharmacother 10:1841-5. 2009
    ..While the opioid receptor antagonist naltrexone is associated with minimal weight loss as monotherapy, it does have potential utility in the treatment of obesity when combined with the pro-opiomelanocortin activator bupropion...
  5. pmc Nalfurafine prevents 5'-guanidinonaltrindole- and compound 48/80-induced spinal c-fos expression and attenuates 5'-guanidinonaltrindole-elicited scratching behavior in mice
    S Inan
    Department of Pharmacology, Temple University School of Medicine, 3420 North Broad Street, Philadelphia, PA 19140, USA
    Neuroscience 163:23-33. 2009
    ..On the basis of our results, nalfurafine holds promise as a potentially useful antipruritic in human conditions involving itch...
  6. ncbi Association of µ-opioid receptor (OPRM1) gene polymorphism with response to naltrexone in alcohol dependence: a systematic review and meta-analysis
    Antonio Javier Chamorro
    Department of Internal Medicine, Hospital of Ourense, Spain
    Addict Biol 17:505-12. 2012
    ..This genetic marker may therefore identify a subgroup of individuals more likely to respond to this treatment...
  7. pmc Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful?
    NATALYA C MAISEL
    Center for Health Care Evaluation, VA Palo Alto Health Care System 152MPD, Menlo Park, CA 94025, USA
    Addiction 108:275-93. 2013
    ....
  8. ncbi Activation of stress-related hypothalamic neuropeptide gene expression during morphine withdrawal
    Cristina Nunez
    Department of Pharmacology, University of Murcia, Murcia, Spain
    J Neurochem 101:1060-71. 2007
    ..These activations however were not associated with induction of CRH or AVP hnRNAs...
  9. ncbi Pharmacological properties of JDTic: a novel kappa-opioid receptor antagonist
    Ivy Carroll
    Organic and Medicinal Chemistry, Research Triangle Institute, Research Triangle Park, North Carolina, USA
    Eur J Pharmacol 501:111-9. 2004
    ..In the U50,488-induced diuresis rat test, JDTic, s.c., suppressed diuretic activity with a greater potency than that of nor-binaltorphimine (nor-BNI). Thus, JDTic is a potent long- and orally acting selective kappa-opioid antagonist...
  10. ncbi Chronic exposure to mu-opioid agonists produces constitutive activation of mu-opioid receptors in direct proportion to the efficacy of the agonist used for pretreatment
    J G Liu
    Department of Pharmacology and Toxicology, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA
    Mol Pharmacol 60:53-62. 2001
    ..These observations may lend novel insight into the mechanisms of opioid tolerance and dependence...
  11. ncbi Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone
    Paul J Fudala
    Veterans Affairs VA Medical Center, University of Pennsylvania School of Medicine, Philadelphia, USA
    N Engl J Med 349:949-58. 2003
    ..Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone has been proposed, but its efficacy and safety have not been well studied...
  12. ncbi Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial
    Thomas A Wadden
    Department of Psychiatry, Center for Weight and Eating Disorders, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    Obesity (Silver Spring) 19:110-20. 2011
    ..The present findings support the efficacy of combined naltrexone/bupropion therapy as an adjunct to intensive BMOD for obesity...
  13. ncbi From taste hedonics to motivational drive: central μ-opioid receptors and binge-eating behaviour
    Pradeep J Nathan
    Brain Mapping Unit, Department of Psychiatry, University of Cambridge, Cambridge, UK
    Int J Neuropsychopharmacol 12:995-1008. 2009
    ....
  14. pmc Distinguishing signs of opioid overdose and indication for naloxone: an evaluation of six overdose training and naloxone distribution programs in the United States
    Traci C Green
    Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, CT 06520 8034, USA
    Addiction 103:979-89. 2008
    ..This study assessed overdose and naloxone administration knowledge among current or former opioid abusers trained and untrained in overdose-response in the United States...
  15. ncbi Cannabinoids, opioids and eating behavior: the molecular face of hedonism?
    Daniela Cota
    Obesity Research Center, Department of Psychiatry, University of Cincinnati Genome Research Institute, 2170 E Galbraith Road, Cincinnati, OH 45237, USA
    Brain Res Rev 51:85-107. 2006
    ....
  16. ncbi Prescribing naloxone to actively injecting heroin users: a program to reduce heroin overdose deaths
    Sarz Maxwell
    Chicago Recovery Alliance, Chicago, IL, USA
    J Addict Dis 25:89-96. 2006
    ..This trend reversed in 2001, with a 20% decrease in 2001 and 10% decreases in 2002 and 2003...
  17. ncbi Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial
    Raymond F Anton
    Center for Drug and Alcohol Programs, Medical University of South Carolina, Charleston 29425, USA
    JAMA 295:2003-17. 2006
    ..Alcohol dependence treatment may include medications, behavioral therapies, or both. It is unknown how combining these treatments may impact their effectiveness, especially in the context of primary care and other nonspecialty settings...
  18. ncbi Provision of naloxone to injection drug users as an overdose prevention strategy: early evidence from a pilot study in New York City
    Sandro Galea
    Center for Urban Epidemiologic Studies, New York Academy of Medicine, New York, NY 10029, USA
    Addict Behav 31:907-12. 2006
    ..However, there has been little documented evidence of naloxone distribution programs and their feasibility in the peer reviewed literature in the US...
  19. pmc The BRENDA model: integrating psychosocial treatment and pharmacotherapy for the treatment of alcohol use disorders
    Aron N Starosta
    University of Pennsylvania, PA 19104, USA
    J Psychiatr Pract 12:80-9. 2006
    ..This paper describes these components and discusses how the empirical support for each component is linked to the enhancement of medication compliance and the improvement of treatment outcomes...
  20. ncbi Opioid receptor blockade in rat nucleus tractus solitarius alters amygdala dynorphin gene expression
    Michael J Glass
    Weill Medical College, Cornell University, New York, NY 10021, USA
    Am J Physiol Regul Integr Comp Physiol 283:R161-7. 2002
    ..Thus chronic administration of naltrexone in the NTS increased dynorphin gene expression in the amygdala, further supporting an opioidergic feeding pathway between these two brain sites...
  21. ncbi The endogenous opioid system is not involved in modulation of opioid-induced hyperalgesia
    Larry F Chu
    Department of Anesthesia, Stanford University School of Medicine, 300 Pasteur Drive, Stanford, CA 94305, USA
    J Pain 12:108-15. 2011
    ..These results suggested that the endogenous opioid system did not appear to modulate OIH...
  22. pmc The kappa opioid receptor antagonist JDTic attenuates alcohol seeking and withdrawal anxiety
    Jesse R Schank
    Laboratory of Clinical and Translational Studies, National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD, USA
    Addict Biol 17:634-47. 2012
    ..Our results provide additional evidence for the involvement of KOR in regulation of alcohol-related behaviors and provide support for KOR antagonists, including JDTic, to be evaluated as medications for alcoholism...
  23. ncbi A randomised trial of the cost effectiveness of buprenorphine as an alternative to methadone maintenance treatment for heroin dependence in a primary care setting
    Anthony H Harris
    Centre for Health Program Evaluation, Monash University, Melbourne, Australia
    Pharmacoeconomics 23:77-91. 2005
    ..This study is the first to examine the cost effectiveness of buprenorphine as maintenance treatment for heroin dependence in a primary care setting using economic and clinical data collected within a randomised trial...
  24. ncbi Selective mu- and kappa-opioid receptor antagonists administered into the nucleus accumbens interfere with rapid tolerance to ethanol in rats
    Rafael Koerich Varaschin
    Departamento de Farmacologia, Centro de Ciencias Biologicas, CCB, Universidade Federal de Santa Catarina, Campus Universitario Trindade, 88049 900, Florianopolis, Santa Catarina, Brazil
    Psychopharmacology (Berl) 206:85-96. 2009
    ..This study investigates the effects of intra-accumbens injection of the selective mu-, delta-, and kappa-opioid antagonists, respectively, naloxonazine, naltrindole, and nor-binaltorphimine, on rapid tolerance to ethanol...
  25. pmc Naloxone, but not valsartan, preserves responses to hypoglycemia after antecedent hypoglycemia: role of metabolic reprogramming in counterregulatory failure
    Michal M Poplawski
    Fishberg Center for Neurobiology, Mount Sinai School of Medicine, New York, New York, USA
    Diabetes 60:39-46. 2011
    ..The goal of this study was to generate novel hypothalamic markers of hypoglycemia and use them to assess mechanisms mediating HAAF and its reversal...
  26. pmc Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings
    Ira L Mintzer
    Harvard Medical School Cambridge Health Alliance, Cambridge, MA 02139, USA
    Ann Fam Med 5:146-50. 2007
    ..Efficacy of this treatment in non-research clinical settings has not been studied. We examined the efficacy and practicality of buprenorphine-naloxone treatment in primary care settings...
  27. ncbi Deletion of CCK2 receptor in mice results in an upregulation of the endogenous opioid system
    Blandine Pommier
    Departement de Pharmacochimie Moleculaire et Structurale, Institut National de la Santé et de la Recherche Médicale U266 Centre National de la Recherche Scientifique Unité Mixte de Recherche 8600, Paris Cedex 06, France
    J Neurosci 22:2005-11. 2002
    ..These biochemical and pharmacological results demonstrate the critical role played by CCK2 receptors in opioid-dependent responses...
  28. pmc Distinct opioid circuits determine the palatability and the desirability of rewarding events
    K M Wassum
    Department of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, CA 90024, USA
    Proc Natl Acad Sci U S A 106:12512-7. 2009
    ..Rather, changes in palatability and in the incentive value assigned to rewarding events seem to be mediated by distinct neural processes...
  29. pmc Naltrexone for the management of alcohol dependence
    Raymond F Anton
    Center for Drug and Alcohol Programs, Medical University of South Carolina, Charleston 29425, USA
    N Engl J Med 359:715-21. 2008
  30. ncbi Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence
    David A Fiellin
    Department of Internal Medicine, Yale University School of Medicine, New Haven, Conn 06520, USA
    N Engl J Med 355:365-74. 2006
    ..The optimal level of counseling and frequency of attendance for medication distribution has not been established for the primary care, office-based buprenorphine-naloxone treatment of opioid dependence...
  31. ncbi Therapeutic drug monitoring for drugs used in the treatment of substance-related disorders: literature review using a therapeutic drug monitoring appropriateness rating scale
    Sonja Brünen
    Department of Psychiatry and Psychotherapy, University Medical Center of Mainz, Mainz, Germany
    Ther Drug Monit 33:561-72. 2011
    ..Because TDM for most of those drugs is not established, the authors reviewed the literature and built a rating scale to detect the potential added value of TDM for these pharmacologic agents...
  32. ncbi Antiallodynic effects of intrathecal orexins in a rat model of postoperative pain
    Jen Kun Cheng
    Department of Pharmacology, College of Medicine, National Taiwan University, 1, Jen Ai Rd, Section 1, Taipei 100, Taiwan
    J Pharmacol Exp Ther 307:1065-71. 2003
    ..Endogenous orexin might be released after incision injury to activate the spinal OX1 receptors as an endogenous analgesic protector...
  33. pmc Pharmacological differentiation of opioid receptor antagonists by molecular and functional imaging of target occupancy and food reward-related brain activation in humans
    E A Rabiner
    GSK Clinical Imaging Centre, Imperial College London, Hammersmith Hospital, London, UK
    Mol Psychiatry 16:826-35, 785. 2011
    ..Pharmacological differentiation of these molecules suggests that they may have different therapeutic profiles for treatment of overeating and other disorders of compulsive consumption...
  34. ncbi Naltrexone for the treatment of alcoholism: a meta-analysis of randomized controlled trials
    Manit Srisurapanont
    Department of Psychiatry, Faculty of Medicine, Chiang Mai University, Amphur Muang, Chiang Mai 50200, Thailand
    Int J Neuropsychopharmacol 8:267-80. 2005
    ..To ensure that the real-world treatment is as effective as the research findings, a form of psychosocial therapy should be concomitantly given to all alcohol-dependent patients receiving naltrexone administration...
  35. ncbi Buprenorphine: how to use it right
    Rolley E Johnson
    Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, 5510 Nathan Shock Drive, Baltimore, MD 21224, USA
    Drug Alcohol Depend 70:S59-77. 2003
    ....
  36. ncbi Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis
    Bruce A C Cree
    Multiple Sclerosis Center at University of California, San Francisco, 94117, USA
    Ann Neurol 68:145-50. 2010
    ..To evaluate the efficacy of 4.5mg nightly naltrexone on the quality of life of multiple sclerosis (MS) patients...
  37. ncbi Differential regulation of the consummatory, motivational and anticipatory aspects of feeding behavior by dopaminergic and opioidergic drugs
    Maria Flavia Barbano
    Laboratoire de Neuropsychobiologie des Desadaptations, Centre National de la Recherche Scientifique, Unite Mixte de Recherche 5541, Universite Victor Segalen Bordeaux 2, Bordeaux, France
    Neuropsychopharmacology 31:1371-81. 2006
    ..The dopaminergic system seems to be more important for the regulation of anticipatory activity related to motivationally relevant stimuli...
  38. ncbi The cost-effectiveness of buprenorphine maintenance therapy for opiate addiction in the United States
    P G Barnett
    Health Economics Resource Center, Veterans Affairs Palo Alto Health Care System, Menlo Park, CA, USA and the Department of Health Research and Policy, Stanford University, Stanford, CA, USA
    Addiction 96:1267-78. 2001
    ..To determine the cost-effectiveness of buprenorphine maintenance therapy for opiate addiction in the United States, particularly its effect on the HIV epidemic...
  39. ncbi In vivo characterization of 6beta-naltrexol, an opioid ligand with less inverse agonist activity compared with naltrexone and naloxone in opioid-dependent mice
    Kirsten M Raehal
    Department of Pharmacology, University of New England College of Osteopathic Medicine, Biddeford, ME 04005, USA
    J Pharmacol Exp Ther 313:1150-62. 2005
    ..A reduction of withdrawal effects associated with neutral mu-opioid receptor antagonists may offer advantages in treating opioid overdose and addiction...
  40. ncbi Different effects of opioid antagonists on mu-, delta-, and kappa-opioid receptors with and without agonist pretreatment
    Danxin Wang
    Department of Pharmacology, School of Medicine and Public Health, The Ohio State University, 333 West 10th Ave, Columbus, OH 43210, USA
    J Pharmacol Exp Ther 321:544-52. 2007
    ..Activity profiles at the three opioid receptors under different conditions could lead to antagonists with optimal clinical properties in treatment of addiction and adverse opioid effects...
  41. ncbi Opioid-induced cardioprotection occurs via glycogen synthase kinase beta inhibition during reperfusion in intact rat hearts
    Eric R Gross
    Medical College of Wisconsin, Department of Pharmacology and Toxicology, 8701 Watertown Plank Rd, Milwaukee, WI 53226, USA
    Circ Res 94:960-6. 2004
    ..Furthermore, no differences were seen in phosphorylation of GSKalpha (Ser21 or Tyr279) or phosphorylation of GSKbeta (Tyr216). These data indicate that OIC occurs via the phosphorylation of GSKbeta at Ser9 during reperfusion...
  42. ncbi Morphine preconditioning attenuates neutrophil activation in rat models of myocardial infarction
    T L Wang
    Department of Emergency Medicine, Shin Kong Wu Ho Su Memorial Hospital, Taipei, Taiwan
    Cardiovasc Res 40:557-63. 1998
    ..IS/AAR were definitely lowest for those with morphine PC (24 +/- 7%; p < 0.05). Morphine preconditioning increases NEP activities to attenuate shedding of gp100MEL14 and to ICAM-1 and, thus, provides myocardial protection...
  43. ncbi Morphine postconditioning protects against reperfusion injury in the isolated rat hearts
    Zuolei Chen
    Department of Anesthesiology, Affiliated Beijing Tongren Hospital, Capital University of Medical Science, Beijing, China
    J Surg Res 145:287-94. 2008
    ....
  44. ncbi Antinociceptive and morphine modulatory actions of spinal orphanin FQ
    K H Jhamandas
    Department of Pharmacology and Toxicology, Queen s University, Kingston, ON, Canada
    Can J Physiol Pharmacol 76:314-24. 1998
    ..5 nmol) produced a significant decline in their antinociceptive effects. Thus, intrathecally administered OFQ produces both development of tolerance to its antinociceptive actions and cross-tolerance to the action of morphine...
  45. ncbi Opioids and opioid receptors in the enteric nervous system: from a problem in opioid analgesia to a possible new prokinetic therapy in humans
    Peter Holzer
    Department of Experimental and Clinical Pharmacology, Medical University of Graz, Universitatsplatz 4, A 8010 Graz, Austria
    Neurosci Lett 361:192-5. 2004
    ..There is emerging evidence that opioid receptor antagonists may also have prokinetic actions, reversing pathological states of gastrointestinal hypomotility that are due to overactivity of the enteric opioid system...
  46. pmc Attitudes about prescribing take-home naloxone to injection drug users for the management of heroin overdose: a survey of street-recruited injectors in the San Francisco Bay Area
    Karen H Seal
    Department of Family and Community Medicine, University of California, San Francisco, CA 94110, USA
    J Urban Health 80:291-301. 2003
    ..Nevertheless, strategies for overcoming potential risks associated with the use of take-home naloxone would need to be emphasized in an overdose management training program...
  47. ncbi Nociceptin/orphanin FQ in spinal nociceptive mechanisms under normal and pathological conditions
    X Xu
    Department of Medical Laboratory Sciences and Technology, Division of Clinical Neurophysiology, Karolinska Institutet, S 141 86, Huddinge, Sweden
    Peptides 21:1031-6. 2000
    ..The physiological role of nociceptin in spinal nociceptive mechanisms remains to be defined. Moreover, further evaluation of nociceptin as a new analgesic calls the development of non-peptide brain penetrating agents...
  48. pmc Long-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain
    A Sandner-Kiesling
    Department of Anaesthesiology and Intensive Care Medicine, Medical University, Graz, Austria
    Int J Clin Pract 64:763-74. 2010
    ....
  49. ncbi Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomised controlled trial
    O Lowenstein
    Mundipharma Research GmbH and Co KG, Limburg Lahn, Germany
    Expert Opin Pharmacother 10:531-43. 2009
    ....
  50. ncbi Delta-opioid receptor-mediated increase in cortical extracellular levels of cholecystokinin-like material by subchronic morphine in rats
    C Becker
    INSERM U 288, NeuroPsychoPharmacologie Moléculaire, Cellulaire et Fonctionnelle, C H U Pitiè Salpêtrière, Paris, France
    Neuropharmacology 39:161-71. 2000
    ..These data indicate that morphine tolerance is associated with delta-opioid receptor mediated activation of cortical CCKergic systems in rats...
  51. ncbi Interest in smoking cessation among injection drug users
    J G Clarke
    Department of Medicine and Community Health, Brown University School of Medicine, Providence, Rhode Island, USA
    Am J Addict 10:159-66. 2001
    ..Although smoking cessation counseling should be offered to all smokers, interventions directed towards older individuals enrolled in MMTP may target the group most interested in smoking cessation...
  52. ncbi Potentiated opioid analgesia in norepinephrine transporter knock-out mice
    L M Bohn
    Howard Hughes Medical Institute, Departments of Cell Biology and Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Neurosci 20:9040-5. 2000
    ..In summary, these results demonstrate in a genetic model that both endogenous and exogenous opiate-mediated analgesia can be enhanced by elimination of the NET, indicating that the interaction of TCAs with NET mediates these effects...
  53. pmc Opioid-sensitive GABA inputs from rostromedial tegmental nucleus synapse onto midbrain dopamine neurons
    Aya Matsui
    Vollum Institute, Oregon Health and Science University, Portland, Oregon 97239, USA
    J Neurosci 31:17729-35. 2011
    ....
  54. ncbi An open-label study of naltrexone and bupropion combination therapy for smoking cessation in overweight and obese subjects
    Charles S Wilcox
    Pharmacology Research Institute, Los Alamitos, CA, USA
    Addict Behav 35:229-34. 2010
    ..In overweight or obese smokers, naltrexone/bupropion combination therapy with behavioral counseling was associated with decreased nicotine use, limited nicotine withdrawal symptoms, and no significant weight gain...
  55. ncbi Subjective effects and safety of whole and tampered morphine sulfate and naltrexone hydrochloride (ALO-01) extended-release capsules versus morphine solution and placebo in experienced non-dependent opioid users: a randomized, double-blind, placebo-contro
    Joseph Stauffer
    Alpharma Pharmaceuticals LLC, a wholly owned subsidiary of King Pharmaceuticals, Inc, Bridgewater, New Jersey, USA
    Clin Drug Investig 29:777-90. 2009
    ..The purpose of this study was to assess the pharmacodynamic effects (including drug-liking and euphoria) of whole and crushed ALO-01 versus morphine sulfate solution (MSS) and placebo...
  56. ncbi Blood naltrexone levels over time following naltrexone implant
    H T T Ngo
    School of Psychiatry and Clinical Neurosciences, University of Western Australia, QE II Medical Centre, D Block, Nedlands, Western Australia 6009, Australia
    Prog Neuropsychopharmacol Biol Psychiatry 32:23-8. 2008
    ..The study's objective was to determine the period of therapeutic coverage (>or=2 ng/ml) provided by a 3.3 g naltrexone subcutaneous implant compared with existing data on 1.1 g and 2.2 g implants...
  57. pmc Altered responsiveness to cocaine and increased immobility in the forced swim test associated with elevated cAMP response element-binding protein expression in nucleus accumbens
    A M Pliakas
    Department of Psychiatry, Harvard Medical School, McLean Hospital, Belmont, Massachusetts 02478, USA
    J Neurosci 21:7397-403. 2001
    ..Exposure to the FST itself dramatically increased CREB function in the NAc. These findings raise the possibility that CREB-mediated transcription within the NAc regulates dysphoric states...
  58. ncbi 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial
    Johan Kakko
    Division of Psychiatry, Neurotec, Karolinska Institute, Huddinge University Hospital, S 141 86, Stockholm, Sweden
    Lancet 361:662-8. 2003
    ..We aimed to assess the 1-year efficacy of buprenorphine in combination with intensive psychosocial therapy for treatment of heroin dependence...
  59. ncbi Efficacy of maintenance treatment with naltrexone for opioid dependence: a meta-analytical review
    Björn Axel Johansson
    Department of Clinical Alcohol Research, Malmo University Hospital, Lund University, Malmo, Sweden
    Addiction 101:491-503. 2006
    ..To determine the efficacy of naltrexone in reducing illicit opioid use and the potential moderating role of treatment retention...
  60. ncbi A trial of integrated buprenorphine/naloxone and HIV clinical care
    Lynn E Sullivan
    Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06520 8025, USA
    Clin Infect Dis 43:S184-90. 2006
    ..We investigated the feasibility and efficacy of integrating buprenorphine, along with 2 levels of counseling, into HIV clinical care...
  61. pmc Blocking central opiate function modulates hedonic impact and anterior cingulate response to rewards and losses
    Predrag Petrovic
    Wellcome Trust Centre for Neuroimaging, University College London, London WC1N 3BG, United Kingdom
    J Neurosci 28:10509-16. 2008
    ..Our data indicate that a central opioid system contributes to both reward and loss processing in humans and directly modulates the hedonic experience of outcomes...
  62. ncbi Kappa opioid antagonist effects of the novel kappa antagonist 5'-guanidinonaltrindole (GNTI) in an assay of schedule-controlled behavior in rhesus monkeys
    S Stevens Negus
    Alcohol and Drug Abuse Research Center, Harvard Medical School, McLean Hospital, 115 Mill Street, Belmont, MA 02478, USA
    Psychopharmacology (Berl) 163:412-9. 2002
    ..Receptor-selective antagonists are useful experimental tools for evaluation of opioid receptor-mediated processes. 5'-Guanidinonaltrindole (GNTI) was recently developed as a novel kappa-selective antagonist...
  63. ncbi Antinociceptive activity of aqueous extract of Bowdichia virgilioides in mice
    Juliane P Silva
    Instituto de Ciências Biológicas e da Saúde, Universidade Federal de Alagoas, Maceio, Brazil
    J Med Food 13:348-51. 2010
    ..o. Our findings show that B. virgilioides contains pharmacologically active constituents that possess antinociceptive activity justifying its popular therapeutic use in treating conditions associated with the painful conditions...
  64. ncbi Effects of buprenorphine/naloxone in opioid-dependent humans
    K B Stoller
    Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, 5510 Nathan Shock Drive, Baltimore, MD 21224, USA
    Psychopharmacology (Berl) 154:230-42. 2001
    ..Low doses of injected buprenorphine/naloxone have been tested in opioid-dependent subjects, but higher doses (more than 2 mg of either medication) and direct comparisons to SL buprenorphine/naloxone have not been examined...
  65. ncbi Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats
    Stephen D Mague
    Behavioral Genetics Laboratory, Department of Psychiatry, Harvard Medical School, McLean Hospital, Belmont, Massachusetts 02478, USA
    J Pharmacol Exp Ther 305:323-30. 2003
    ..Furthermore, they raise the possibility that kappa-antagonists may have efficacy as antidepressants, but lack stimulant or reward-related effects...
  66. pmc Opioids in the hypothalamus control dopamine and acetylcholine levels in the nucleus accumbens
    Pedro Rada
    Laboratory of Behavioral Physiology, School of Medicine, University of Los Andes, Merida, Venezuela
    Brain Res 1312:1-9. 2010
    ....
  67. pmc Kappa opioid antagonists: past successes and future prospects
    Matthew D Metcalf
    Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, 20 Penn Street, Baltimore, MD 21201, USA
    AAPS J 7:E704-22. 2005
    ....
  68. ncbi Efficacy of nociceptin inhibition on WDR neuron activity is enhanced in mononeuropathic rats
    Maria Luisa Sotgiu
    Istituto Bioimmagini e Fisiologia Molecolare, CNR, Via Fratelli Cervi 93, 20090 Segrate Mi, Italy
    Brain Res 998:251-4. 2004
    ..The same concentrations of NC were ineffective on the noxious stimulus evoked responses of WDR neurons in sham and intact rats. This result indicates a facilitated inhibitory action of NC on nociceptive transmission in this pain model...
  69. ncbi In vivo and in vitro characterization of naltrindole-derived ligands at the κ-opioid receptor
    Joseph J Casal-Dominguez
    Department of Pharmacy and Pharmacology, University of Bath, Bath, UK
    J Psychopharmacol 27:192-202. 2013
    ..Interestingly, while 5'-AMN and 5'-MABN were not κ-selective, both compounds did show significant antidepressant- and anxiolytic-like effects at 7-14 days post-injection in mice...
  70. pmc Long-acting κ opioid antagonists nor-BNI, GNTI and JDTic: pharmacokinetics in mice and lipophilicity
    Thomas A Munro
    McLean Hospital, Belmont, MA and Department of Psychiatry, Harvard Medical School, Boston, MA, USA
    BMC Pharmacol 12:5. 2012
    ..Recent evidence suggests, instead, that they induce prolonged desensitization of the κ opioid receptor...
  71. ncbi Supraspinal and spinal cord opioid receptors are responsible for antinociception following intrathecal morphine injections
    C S Goodchild
    Monash University Department of Anaesthesia, Monash Medical Centre, Clayton, Victoria, Australia
    Eur J Anaesthesiol 21:179-85. 2004
    ..Experiments were performed on male Wistar rats with chronically implanted lumbar subarachnoid catheters...
  72. ncbi Achieving long-term continuous blood naltrexone and 6-beta-naltrexol coverage following sequential naltrexone implants
    G K Hulse
    Unit for Research and Education in Drugs and Alcohol, School of Psychiatry and Clinical Neurosciences, University of Western Australia, Perth, Australia
    Addict Biol 9:67-72. 2004
    ..4 g naltrexone implants. These extended periods of coverage will offer significant benefits for managing the heroin-dependent patient...
  73. ncbi The impact of buprenorphine on treatment of opioid dependence in a Medicaid population: recent service utilization trends in the use of buprenorphine and methadone
    Bradley D Stein
    Community Care Behavioral Health Organization, Pittsburgh, PA 15219, USA
    Drug Alcohol Depend 123:72-8. 2012
    ....
  74. pmc Can the chronic administration of the combination of buprenorphine and naloxone block dopaminergic activity causing anti-reward and relapse potential?
    Kenneth Blum
    Department of Psychiatry and McKnight Brain Institute, University of Florida College of Medicine, Gainesville, FL 32610, USA
    Mol Neurobiol 44:250-68. 2011
    ..However, more than anything else this commentary should at least encourage the development of thoughtful new strategies to target the specific brain regions responsible for relapse prevention...
  75. pmc Adoption and implementation of medications in addiction treatment programs
    Hannah K Knudsen
    Department of Behavioral Science and Center on Drug and Alcohol Research, College of Medicine, University of Kentucky, Lexington, KY 40536 0086, USA
    J Addict Med 5:21-7. 2011
    ..Little is known about the extent to which medications are being implemented as routine care in addiction treatment programs. This research describes medication adoption and implementation within the privately funded treatment sector...
  76. ncbi Buprenorphine in the treatment of opiate dependence
    Donald R Wesson
    CNS Medications Development, Oakland, CA, USA
    J Psychoactive Drugs 42:161-75. 2010
    ..This article reviews the pharmacology of buprenorphine, summarizes evidence supporting the safety and efficacy of buprenorphine and provides clinical guidelines for treatment...
  77. ncbi Use of buprenorphine in pregnancy: patient management and effects on the neonate
    Rolley E Johnson
    Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA
    Drug Alcohol Depend 70:S87-101. 2003
    ..From a review of the literature, buprenorphine appears to be safe and effective in both mother and infant with an NAS that may differ from methadone both qualitatively and quantitatively...
  78. pmc Potency of naltrexone to reduce ethanol self-administration in rats is greater for subcutaneous versus intraperitoneal injection
    Keith L Williams
    Department of Psychology, Oakland University, 224 Pryale Hall, Rochester, MI 48309, USA
    Alcohol 43:119-26. 2009
    ..These findings further support the notion that NTX acts by terminating responding early rather than reducing the initial responding...
  79. ncbi What heroin users tell us about overdose
    Catherine T Baca
    Center on Alcoholism, Substance Abuse, and Addictions CASAA, 2650 Yale SE, Albuquerque, NM 87106, USA
    J Addict Dis 26:63-8. 2007
    ..New methods need to be found to reduce heroin overdose death. Scientific studies are needed on the efficacy of take-home naloxone...
  80. pmc κ-Opioid receptors in the central amygdala regulate ethanol actions at presynaptic GABAergic sites
    Maenghee Kang-Park
    Department of Psychiatry, Duke University Medical Center, and Research Service, Veterans Administration Medical Center, Durham, North Carolina 27705, USA
    J Pharmacol Exp Ther 346:130-7. 2013
    ..Our data support the idea that KORs modulate GABAergic synaptic responses and ethanol effects as one of multiple opioid system-dependent actions of ethanol in the CeA, possibly in a circuit-specific manner...
  81. ncbi Expression of morphine-conditioned place preference is more vulnerable than naloxone-conditioned place aversion to disruption by nociceptin in mice
    Kazuto Sakoori
    Molecular Neuropathology Group, RIKEN Brain Science Institute, Wakoshi, Saitama 351 0198, Japan
    Neurosci Lett 443:108-12. 2008
    ..These results suggest that nociceptin more potently blocks the ability of reward-associated cues than aversion-associated cues to influence behavioral biases...
  82. ncbi Blockade of the antinociceptive effect of spinally administered kyotorphin by naltrindole in mice
    Takehiro Ochi
    Department of Immunology and Inflammation, Medicinal Biology Research Laboratories, Fujisawa Pharmaceutical Co Ltd, 1 6, Kashima 2 chome, Yodogawa ku, Osaka, Japan
    Neurosci Lett 322:95-8. 2002
    ..These results suggest that KTP-induced antinociception is mediated by binding to KTP receptors followed by an indirect activation of the delta-opioid receptors in the spinal cord...
  83. pmc Data on take home naloxone are unclear but not condemnatory
    Dan Bigg
    BMJ 324:678. 2002
  84. ncbi Endogenous kappa opioid activation mediates stress-induced deficits in learning and memory
    Amanda N Carey
    Department of Psychology, Northeastern University, Boston, Massachusetts 02115 5000, USA
    J Neurosci 29:4293-300. 2009
    ..8%) demonstrated by their wild-type littermates (RI=49.7+/-2.9%). Overall, these results suggest that stress-induced activation of the KOR may be both necessary and sufficient to produce subsequent deficits in novel object recognition...
  85. ncbi Transplacental transfer and metabolism of buprenorphine
    Tatiana Nanovskaya
    Division of Pharmacology, School of Medicine, University of Missouri, Kansas City, Missouri 64108 2792, USA
    J Pharmacol Exp Ther 300:26-33. 2002
    ..The observed low transplacental transfer of BUP to the fetal circuit may explain the moderate/absence of neonatal withdrawal in the limited number of reports on mothers treated with the drug during pregnancy...
  86. ncbi Overdose training and take-home naloxone for opiate users: prospective cohort study of impact on knowledge and attitudes and subsequent management of overdoses
    John Strang
    National Addiction Centre Institute of Psychiatry The Maudsley, Addiction Sciences Building, Denmark Hill, London, UK
    Addiction 103:1648-57. 2008
    ..To examine the impact of training in overdose management and naloxone provision on the knowledge and confidence of current opiate users; and to record subsequent management of overdoses that occur during a 3-month follow-up period...
  87. ncbi Inverse agonist up-regulates the constitutively active D3.49(164)Q mutant of the rat mu-opioid receptor by stabilizing the structure and blocking constitutive internalization and down-regulation
    J Li
    Department of Pharmacology, Temple University School of Medicine, Philadelphia, Pennsylvania 19140, USA
    Mol Pharmacol 60:1064-75. 2001
    ..To the best of our knowledge, this represents the first comprehensive analysis of the mechanisms involved in up-regulation of constitutively active mutants by an inverse agonist...
  88. ncbi Involvement of endogenous opioid systems in nociceptin-induced spinal antinociception in rats
    Long Chuan Yu
    Department of Anesthesia and Perioperative Care, University of California, Box 0464, Room S 455 513 Parnassus Avenue, San Francisco, CA 94143, USA
    Brain Res 945:88-96. 2002
    ..Since it is unlikely that nociceptin acts by direct binding to opioid receptors, these results suggest a possible interaction between the nociceptin/ORL1 and opioid systems in the dorsal horn of the rat spinal cord...
  89. ncbi P-glycoprotein is not involved in the differential oral potency of naloxone and naltrexone
    Mouna Kanaan
    Clinical Pharmacology, Geneva University Hospitals, Faculty of Medicine, University of Geneva, CH 1211 Geneva 14, Switzerland
    Fundam Clin Pharmacol 23:543-8. 2009
    ..05). In conclusion, NA and NX are not P-gp substrates. The differential oral bioavailability of the two opioid antagonists is P-gp independent...
  90. ncbi Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users
    Hannu Alho
    National Public Health Institute, Department of Mental Health and Alcohol Research, Helsinki, Finland
    Drug Alcohol Depend 88:75-8. 2007
    ..Its street price was less than half that of buprenorphine alone. The buprenorphine+naloxone combination appears to be a feasible tool, along with easier access to addiction treatment, for decreasing IV abuse of buprenorphine...
  91. ncbi Opioid overdose deaths can occur in patients with naltrexone implants
    Colin L Brewer
    Med J Aust 187:55; author reply 56-7. 2007
  92. ncbi Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients
    Richard P Mattick
    National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Australia
    Addiction 98:441-52. 2003
    ..To assess the efficacy of buprenorphine compared with methadone maintenance therapy for opioid dependence in a large sample using a flexible dosing regime and the marketed buprenorphine tablet...
  93. ncbi Alterations in food intake elicited by GABA and opioid agonists and antagonists administered into the ventral tegmental area region of rats
    Joyce A Echo
    Department of Psychology and Neuropsychology Doctoral Sub Program, Queens College, City University of New York, 65 30 Kissena Boulevard, Flushing, NY 11367, USA
    Physiol Behav 76:107-16. 2002
    ..Therefore, possible coregulation between GABA(B) and opioid receptors in the VTA region, as suggested by immunocytochemical evidence, is supported by these behavioral effects upon ingestion...
  94. pmc A placebo-controlled randomized clinical trial of naltrexone in the context of different levels of psychosocial intervention
    David W Oslin
    Center for the Study of Addictions, Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Alcohol Clin Exp Res 32:1299-308. 2008
    ....
  95. ncbi Buprenorphine and HIV primary care: new opportunities for integrated treatment
    Jag Khalsa
    National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD 20892 9551, USA
    Clin Infect Dis 43:S169-72. 2006
    ....
  96. pmc Novel opioid cyclic tetrapeptides: Trp isomers of CJ-15,208 exhibit distinct opioid receptor agonism and short-acting κ opioid receptor antagonism
    Nicolette C Ross
    Torrey Pines Institute for Molecular Studies, Port St Lucie, FL 34987, USA
    Br J Pharmacol 165:1097-108. 2012
    ....
  97. ncbi Nucleus accumbens opioids regulate flavor-based preferences in food consumption
    J D Woolley
    The Ernest Gallo Clinic and Research Center and the Wheeler Center for the Neurobiology of Addiction, Department of Neurology, University of California, San Francisco, San Francisco, CA 94143, USA
    Neuroscience 143:309-17. 2006
    ..These results indicate that opioid signaling directly regulates a subset of NAcc neurons that can selectively enhance consumption of preferred palatable foods based exclusively on flavor cues...
  98. ncbi Opioid overdose deaths can occur in patients with naltrexone implants
    Gary K Hulse
    Med J Aust 187:54; author reply 56-7. 2007
  99. pmc Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial
    Roger D Weiss
    Division of Alcohol and Drug Abuse, McLean Hospital, Belmont, MA 02478, USA
    Arch Gen Psychiatry 68:1238-46. 2011
    ..No randomized trials have examined treatments for prescription opioid dependence, despite its increasing prevalence...
  100. pmc Saved by the nose: bystander-administered intranasal naloxone hydrochloride for opioid overdose
    Maya Doe-Simkins
    Boston Public Health Commission AHOPE Needle Exchange program, Boston, MA, USA
    Am J Public Health 99:788-91. 2009
    ..Problems with intranasal naloxone were uncommon. Overdose prevention education with distribution of intranasal naloxone is a feasible public health intervention to address opioid overdose...
  101. ncbi What role does measuring medication compliance play in evaluating the efficacy of naltrexone?
    Alicia M Baros
    Charleston Alcohol Research Center, MUSC, Charleston, South Carolina 29425, USA
    Alcohol Clin Exp Res 31:596-603. 2007
    ....

Research Grants65

  1. BIOLOGICAL DISPOSITION OF NARCOTIC ANALGESICS IN MAN
    CARL HUG; Fiscal Year: 1980
    ..to improve our understanding of the actions of narcotic analgesics and narcotic antagonists in man, 2...
  2. BEHAVIORAL PHARMACOLOGY OF NARCOTIC ANTAGONISTS
    STEPHEN HOLTZMAN; Fiscal Year: 2002
    ..Acute agonist-induced sensitization to opioid antagonists appears to be an exquisite example of neuronal plasticity, reflecting the first hours of the drug-receptor interactions that lead to chronic physical dependence upon opioids. ..
  3. PHARMACOLOGY OF NARCOTICS & NARCOTIC ANTAGONISTS
    JAMES MC KEARNEY; Fiscal Year: 1991
    ..In addition to morphine and naloxone, other drugs with differing affinities for the mu- and kappa-opioid receptor subtypes will be studied...
  4. EFFECTIVE NARCOTIC ANTAGONISTS
    Jack Fishman; Fiscal Year: 1980
    ..substrates for metabolic studies, towards unique agonist-antagonist structures designed to explore the nature of the opiate receptors, and most importantly to new categories of narcotic antagonists which would be exceptionally effective.
  5. CHARACTERIZATION OF ETHANOL WITHDRAWAL
    Harbans Lal; Fiscal Year: 1992
    ..experiments will determine the degree to which ethanol, pentobarbital, diazepam, clinidine, morphine and narcotic antagonists modify detection of the PTZ-like stimulus during ethanol withdrawal...
  6. Gene Gun Technology, Opioids, and Corneal Diseases
    IAN ZAGON; Fiscal Year: 2003
    ..Ultimately, such data can be employed to design molecular strategies to remedy visual dysfunction. ..
  7. Cognitive-Behavioral Therapy for Pathological Gambling
    Jon Grant; Fiscal Year: 2008
    ..This award would provide me with the necessary background for further studies in the treatment of pathological gambling and the training for an independent patient-oriented research career. ..
  8. PAIN REGULATORY SYSTEM DYSFUNCTION IN CHRONIC PAIN
    Stephen Bruehl; Fiscal Year: 2002
    ..Greater pain duration is expected to be associated with smaller changes in the BP/pain relationship in response to opioid blockade. ..
  9. Anger Expression, Opioid Dysfunction, and Chronic Pain
    Stephen Bruehl; Fiscal Year: 2009
    ....
  10. Pain Regulatory Dysfunction in Chronic Pain
    Stephen Bruehl; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  11. COMMITTEE ON PROBLEMS OF DRUG DEPENDENCE ANNUAL MEETING
    THOMAS BURKS; Fiscal Year: 1990
    ..Michael Kuhar), "Opioids and the Immune System" (Arthur Falek and John Madden), "Therapeutic Potential of Narcotic Antagonists" (William Dewey and John Holaday), "Characterization and Molecular Biology of Multiple Opioid Receptors: an ..
  12. Gabapentin as an Adjunct to Naltrexone for Alcoholism
    Raymond Anton; Fiscal Year: 2006
    ..This evaluation of a novel treatment will allow us to better understand combined pharmacotherapy and develop a new paradigm for medications development for alcoholism. ..
  13. Human Laboratory Model of Cocaine Treatment: Behavioral Economic Analysis
    Mark K Greenwald; Fiscal Year: 2010
    ....
  14. Reducing Cocaine/Heroin Abuse with SR-Amphetamine and Buprenorphine
    Mark Greenwald; Fiscal Year: 2009
    ..The innovative aims, rigorous methods and clinical/public health significance of this project (i.e. whether SR-AMP has potential efficacy for reducing cocaine use) is highly concordant with this RFA. ..
  15. Sustained-Release Naltrexone for Opioid Dependence: Longitudinal Study in Humans
    Sandra D Comer; Fiscal Year: 2010
    ....
  16. SERTRALINE FOR ALCOHOL DEPENDENCE AND DEPRESSION
    Helen Pettinati; Fiscal Year: 2003
    ..Overall, this project will determine if combining pharmacotherapies results in a better response in comorbidly depressed alcoholics than either medication alone or placebo. ..
  17. BEHAVIORAL SUPPORT WITH PHARMACOTHERAPY FOR ALCOHOLICS
    Helen Pettinati; Fiscal Year: 2004
    ..However, each study site has provided site-specific information on the budget, budget justifications, listing of key personnel, consultant/consortium agreements, and human subjects sections of their respective proposals. ..
  18. Counseling for Primary Care Office-Based Buprenorphine
    David Fiellin; Fiscal Year: 2009
    ..The results of this study will help define the role of professional evidence-based drug counseling in expanding access to treatment with Bup. ..
  19. PAIN AND ANALGESIC RESPONSE--SEX AND HORMONE VARIATIONS
    Sandra Comer; Fiscal Year: 2002
    ..In addition, they will more carefully examine sex differences in analgesic response to butorphanol and morphine, two agonists with differing selectivities for mu and kappa opioid receptors. ..
  20. BUPRENORPHINE ABUSE BY HUMANS--LABORATORY STUDIES
    Sandra Comer; Fiscal Year: 2002
    ....
  21. Joint Action Analysis of Poly-drug Withdrawal
    Robert Raffa; Fiscal Year: 2006
    ..g., electrophysiologic or molecular biology techniques. An improved understanding of how withdrawal is influenced by poly-drug abuse could lead to development of enhanced clinical treatment. ..
  22. NALTREXONE & SSRI THERAPY FOR ALCOHOL DEPENDENCE
    STEPHANIE O MALLEY; Fiscal Year: 2004
    ..abstract_text> ..
  23. Evaluation in Primates of Cocaine Esterase for the Treatment of Cocaine Toxicity
    Mei Chuan Ko; Fiscal Year: 2010
    ..Dose-response functions for each enzyme will be obtained repeatedly and blood samples analyzed for titer development so that tolerance to the effects of CocE can be monitored. ..
  24. GENETICS OF COCAINE DEPENDENCE
    HENRY RICHARD KRANZLER; Fiscal Year: 2010
    ..Knowledge of the gene variants will help to identify people at greatest risk of developing the disorder, thereby improving prevention efforts. ..
  25. Sertraline Pharmacotherapy for Alcoholism Subtypes
    Henry Kranzler; Fiscal Year: 2007
    ..abstract_text> ..
  26. Pharmacotherapy for opioid and cocaine dependence
    Bruce Rounsaville; Fiscal Year: 2005
    ..4. To examine depression as a predictor of response. 5. To examine three month follow-up status after completing the treatment trial for continuation in treatment, abstinence from illicit drugs, and depressive symptoms. ..
  27. Planning for a CTSA Application at the University of Connecticut
    Judith Fifield; Fiscal Year: 2006
    ..unreadable] [unreadable] [unreadable]..
  28. Intrathecal Opioid-Induced Pruritus
    Mei Chuan Ko; Fiscal Year: 2003
    ..These studies would provide a systematic understanding of the pharmacology of intrathecal morphine-induced pruritus in primates and establish the basis for identifying potential therapeutically effective antipruritics. ..
  29. Non-response to NTX next steps in managing alcoholism
    David Oslin; Fiscal Year: 2007
    ..abstract_text> ..
  30. METHADONE AND BUPERNORPHINE: ANTE- AND POST-PARTUM
    Hendree Jones; Fiscal Year: 2002
    ..abstract_text> ..
  31. Stabilize Addiction/Affect, Begin Inmates' Interferon for HCV of Liver (STAABIHL)
    Peter Friedmann; Fiscal Year: 2009
    ..Such increased access to therapy would benefit public health and public safety. ..
  32. Trazodone for Sleep Disturbance - Early Alcohol Recovery
    Peter Friedmann; Fiscal Year: 2004
    ..Our extensive contacts with community agencies and substance abuse treatment facilities should enhance follow-up rates. ..
  33. Treating the Partners of Drug Using Preg Women: Stage II
    Hendree Jones; Fiscal Year: 2007
    ..abstract_text> ..
  34. Maternal Opioid Treatment: Human Experimental Research
    Hendree Jones; Fiscal Year: 2008
    ..abstract_text> ..
  35. Tobacco Use in Opioid Agonist treated Pregnant Women
    Hendree Jones; Fiscal Year: 2008
    ..This project will make substantial contributions to the understanding of tobacco use and cessation in pregnant women and the role tobacco has on the incidence and severity of NAS in methadone-maintained women. ..
  36. LINKAGE TO HEALTH SERVICES IN DRUG ABUSE TREATMENT
    Peter Friedmann; Fiscal Year: 2002
    ..This work will improve our understanding of linkage mechanisms and of problem-service matching, and quantify the extent to which medical and psychosocial services are important components of effective drug abuse treatment. ..
  37. TREATMENT OF LATE LIFE DEPRESSION COMPLICATED BY ALCOHOL
    David Oslin; Fiscal Year: 2003
    ..Finally, proposed plans for this MCSDA are well coordinated with the research activities of the Section of Geriatric Psychiatry and the Center for Studies on Addiction. ..
  38. Effective Treatment for Prescription Opioid Abuse
    STACEY SIGMON; Fiscal Year: 2009
    ..Development of efficacious treatments for this emerging population will help to reduce the vast economic and societal costs associated with prescription opioid abuse. ..
  39. HCV Treatment Cost-Effectiveness in 3 IDU Populations
    BRUCE SCHACKMAN; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable] [unreadable]..
  40. ALCOHOLISM AND ENDOGENOUS OPIOID ACTIVITY
    Gary Wand; Fiscal Year: 2008
    ..Fortype specifications, see instructions onpage 6.) RESEARCH GRANT TABLE OF CONTENTS PageNumbers Face Page 1 Description, ..
  41. Effect of Drugs on Myocardial Hypoxia
    Garrett Gross; Fiscal Year: 2009
    ..Information gained from these studies will hopefully lead to new therapies to treat patients with ischemic heart disease. ..
  42. Role of the Amygdala in Opioid Self-administration in Rats with Chronic Pain.
    Thomas Martin; Fiscal Year: 2009
    ....
  43. Novel Delta Opioids: Analgesic Effects & Abuse Liability
    SIDNEY NEGUS; Fiscal Year: 2009
    ....
  44. Hyperalgesia in Methadone Patients: Can it be Treated?
    Margaret Compton; Fiscal Year: 2007
    ..abstract_text> ..
  45. RELAPSE PREVENTION GROUP FOR BIPOLAR SUBSTANCE ABUSERS
    Roger Weiss; Fiscal Year: 2001
    ....
  46. NALTREXONE IN DRINKERS SMOKING RESPONSE
    Andrea King; Fiscal Year: 2002
    ..Examining a targeted treatment combining pharmacotherapy and behavioral treatment for this subgroup is of great importance, as alcohol abusers show increased mortality more due to tobacco than alcohol-related illness. ..
  47. Treating Asthma Patients with Major Depressive Disorder
    E Sherwood Brown; Fiscal Year: 2004
    ....
  48. HIPPOCAMPAL FUNCTION DURING CORTICOSTEROID THERAPY
    E Sherwood Brown; Fiscal Year: 2004
    ..Through this award, the Pl will extend his previous research experience by adding new skills and knowledge which will be used for investigations at the interface of neuroscience and clinical research. ..
  49. Viral neuropathology neuropeptides and epilepsy
    Marylou Solbrig; Fiscal Year: 2005
    ....
  50. Naltrexone for Bipolar Disorder and Alcohol Dependence
    E Sherwood Brown; Fiscal Year: 2006
    ..Alcohol use is the primary outcome, and alcohol craving is the secondary outcome. Manic and depressive symptom severity and the relationship between changes in alcohol use and changes in mood will be expIored. ..
  51. Role of dopamine D1 receptors in morphine withdrawal
    Elena Chartoff; Fiscal Year: 2006
    ..This work may lead to new pharmacotherapies that can alleviate aversive and dysphoric states associated with opiate withdrawal and perhaps reduce relapse to drug taking. ..
  52. Modifying Group Therapy for Bipolar Abusers
    Roger Weiss; Fiscal Year: 2006
    ..If warranted by the results, effect sizes from the proposed study will be used to help in the preparation of a larger-scale subsequent Stage II study. ..
  53. Methadone maintenance and HIV risk in Ukraine
    George Woody; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  54. ACTIONS OF OPIATE DRUGS--DIETARY MODULATION
    ROBIN KANAREK; Fiscal Year: 2002
    ....